Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

References

• Cryotherapy for retinopathy of prematurity cooperative group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Pediatrics. 1988;81(5):697–706.2895910
   PubMedGoogle Scholar
• Early treatment for retinopathy of prematurity cooperative group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–1694.14662586
   PubMedGoogle Scholar
• VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the american academy of ophthalmology. Ophthalmology. 2017;124(5):619–633.28341474
   PubMed Web of Science ®Google Scholar
• Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327–1333.25103848
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–615.21323540
   PubMed Web of Science ®Google Scholar
• Zou L, Lai H, Zhou Q, Xiao F, Haigh JJ. Lasting controversy on ranibizumab and bevacizumab. Theranostics. 2011;1:395–402.22211145
   PubMed Web of Science ®Google Scholar
• Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549–580.15602010
   PubMed Web of Science ®Google Scholar
• Levy AP, Levy NS, Loscalzo J, et al. Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res. 1995;76(5):758–766.7728992
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (lucentis). Ophthalmology. 2007;114(12):2179–2182.18054637
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847–1858. doi:10.1097/IAE.000000000000149328106709
   PubMed Web of Science ®Google Scholar
• Tawse KL, Jeng-Miller KW, Baumal CR. Current practice patterns for treatment of retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):491–495. doi:10.3928/23258160-20160419-1627183557
   PubMed Web of Science ®Google Scholar
• Haigh JJ. Role of vegf in organogenesis. Organogenesis. 2008;4(4):247–256. doi:10.4161/org.4.4.741519337405
   PubMedGoogle Scholar
• Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90(1):e25–e30. doi:10.1111/j.1755-3768.2011.02240.x21958440
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327–333.e321. doi:10.1016/j.ajo.2011.07.00521930258
   PubMed Web of Science ®Google Scholar
• Kong L, Bhatt AR, Demny AB, et al. Pharmacokinetics of bevacizumab and its effects on serum vegf and igf-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956–961. doi:10.1167/iovs.14-1584225613938
   PubMed Web of Science ®Google Scholar
• Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133(4):391–397. doi:10.1001/jamaophthalmol.2014.537325569026
   PubMed Web of Science ®Google Scholar
• Zhou Y, Jiang Y, Bai Y, Wen J, Chen L. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol 2016;254(1):31–6. doi:10.1007/s00417-015-2996-0
   Google Scholar
• Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172(3):278–286. doi:10.1001/jamapediatrics.2017.483829309486
   PubMed Web of Science ®Google Scholar
• Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35(4):675–680. doi:10.1097/IAE.000000000000057825768252
   PubMed Web of Science ®Google Scholar
• Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137:4. doi:10.1542/peds.2015-3218
   Web of Science ®Google Scholar
• Araz-Ersan B, Kir N, Tuncer S, et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Curr Eye Res. 2015;40(6):585–591. doi:10.3109/02713683.2014.94107025025864
   PubMed Web of Science ®Google Scholar
• Lien R, Yu M-H, Hsu K-H, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE. 2016;11(1):e0148019–e0148019. doi:10.1371/journal.pone.014801926815000
   PubMed Web of Science ®Google Scholar
• Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (vegf) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;1:Cd009734.29308602
   PubMed Web of Science ®Google Scholar
• Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity. Retina. 2017;37(4):710–717. doi:10.1097/IAE.000000000000124127529839
   PubMed Web of Science ®Google Scholar
• Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in turkey. Curr Eye Res. 2017;42(3):462–469. doi:10.1080/02713683.2016.119670927420302
   PubMed Web of Science ®Google Scholar
• Alyamac Sukgen E, Comez A, Kocluk Y, Cevher S. The process of retinal vascularization after anti-vegf treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016;236(3):139–147. doi:10.1159/00044953027682852
   PubMed Web of Science ®Google Scholar
• Chen SN, Lian I, Hwang YC, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina. 2015;35(4):667–674. doi:10.1097/IAE.000000000000038025462435
   PubMed Web of Science ®Google Scholar
• Erol MK, Coban DT, Sari ES, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78(6):340–343. doi:10.5935/0004-2749.2015009026677033
   PubMed Web of Science ®Google Scholar
• Kabatas EU, Kurtul BE, Altiaylik Ozer P, Kabatas N. Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in turkish preterm children. Curr Eye Res. 2017;42(7):1054–1058. doi:10.1080/02713683.2016.126460728128986
   PubMed Web of Science ®Google Scholar
• Lin CJ, Tsai YY. Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity. Clin Ophthalmol. 2016;10:1323–1327. doi:10.2147/OPTH.S11071727499611
   PubMedGoogle Scholar
• Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2013;97(7):816–819. doi:10.1136/bjophthalmol-2012-30227623221964
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124(8):1156–1164. doi:10.1016/j.ophtha.2017.03.01828412066
   PubMed Web of Science ®Google Scholar
• Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in china. Ophthalmology. 2017;124(3):408–409. doi:10.1016/j.ophtha.2016.10.03227914833
   PubMed Web of Science ®Google Scholar
• Tong Q, Yin H, Zhao M, Li X, Yu W. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab. BMC Ophthalmol. 2018;18(1):150. doi:10.1186/s12886-018-0815-129940900
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase iii trials: rise and ride. Ophthalmology. 2013;120(10):2013–2022. doi:10.1016/j.ophtha.2013.02.03423706949
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa05448117021318
   PubMed Web of Science ®Google Scholar
• Ahmed IS, Hadi AM, Hassan HH. Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: a case series. Eur J Ophthalmol. Epub 2018 Nov 15.
   Web of Science ®Google Scholar
• Tasman W. Retinopathy of prematurity: do we still have a problem?: the charles l. Schepens lecture. Arch Ophthalmol. 2011;129(8):1083–1086. doi:10.1001/archophthalmol.2011.19221825195
   PubMedGoogle Scholar
• Lemley CA, Han DP. An age-based method for planning sclerotomy placement during pediatric vitrectomy: a 12-year experience. Trans Am Ophthalmol Soc. 2007;105:86–89. discussion 89–91.18427597
   PubMedGoogle Scholar
• Wallace DK, Dean TW, Hartnett ME, et al. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;125(12):1961–1966. doi:10.1016/j.ophtha.2018.05.00129887334
   PubMed Web of Science ®Google Scholar
• Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135(6):654–656. doi:10.1001/jamaophthalmol.2017.105528448664
   PubMed Web of Science ®Google Scholar
• Yonekawa Y, Wu WC, Nitulescu CE, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. 2018;38(6):1079–1083. doi:10.1097/IAE.000000000000168528471890
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–216. doi:10.1136/bjo.2007.12714217965108
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123(9):1845–1855. doi:10.1016/j.ophtha.2016.04.02827241619
   PubMed Web of Science ®Google Scholar